CNS Pharmaceuticals (CNSP) Total Current Liabilities (2018 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Total Current Liabilities came in at $4.1 million in Q4 2025, up 62.46% YoY from $2.5 million in Q4 2024, and up 109.32% on a QoQ basis from $2.0 million in Q3 2025.
CNS Pharmaceuticals (CNSP) Total Current Liabilities (2018 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 8 years of Total Current Liabilities data on file, last reported at $4.1 million in Q4 2025.
- Quarterly Total Current Liabilities rose 62.46% year-over-year to $4.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.1 million (up 62.46% YoY) and the FY2025 annual result came in at $4.1 million, up 62.46% from the prior year.
- Total Current Liabilities grew to $4.1 million in Q4 2025, from $2.0 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $6.8 million in Q2 2024 to a low of $1.4 million in Q2 2025.
- A 5-year average of $3.4 million and a median of $2.7 million in 2021 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Current Liabilities soared 600.89% — and 2025, when it plunged 79.55%.
- Tracing CNSP's Total Current Liabilities over 5 years: stood at $2.6 million in 2021, then surged by 89.66% to $4.9 million in 2022, then increased by 24.65% to $6.1 million in 2023, then slumped by 58.84% to $2.5 million in 2024, then jumped by 62.46% to $4.1 million in 2025.
- The last three Total Current Liabilities figures came in at $4.1 million (Q4 2025), $2.0 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | CNS Pharmaceuticals | 2.64 Mn | -4.56 Mn | - | 4.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.10 Mn |
| Sep 30, 2025 | 1.96 Mn |
| Jun 30, 2025 | 1.38 Mn |
| Mar 31, 2025 | 2.78 Mn |
| Dec 31, 2024 | 2.52 Mn |
| Sep 30, 2024 | 4.06 Mn |
| Jun 30, 2024 | 6.76 Mn |
| Mar 31, 2024 | 6.09 Mn |
| Dec 31, 2023 | 6.13 Mn |
| Sep 30, 2023 | 4.07 Mn |
| Jun 30, 2023 | 4.00 Mn |
| Mar 31, 2023 | 3.92 Mn |
| Dec 31, 2022 | 4.92 Mn |
| Sep 30, 2022 | 2.07 Mn |
| Jun 30, 2022 | 1.75 Mn |
| Mar 31, 2022 | 1.90 Mn |
| Dec 31, 2021 | 2.59 Mn |
| Sep 30, 2021 | 2.41 Mn |
| Jun 30, 2021 | 1.83 Mn |
| Mar 31, 2021 | 1.90 Mn |